New combo aims to mop up hidden cancer cells after myeloma transplant

NCT ID NCT05690984

Ongoing Disease control Sponsor: Medical College of Wisconsin Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a combination of isatuximab, lenalidomide, and dexamethasone can eliminate minimal residual disease (MRD) in multiple myeloma patients who still have detectable cancer cells after a stem cell transplant. About 30 adults will receive the drug combo for up to 12 cycles. The main goal is to see how many become MRD-negative, meaning no cancer cells are found by a sensitive genetic test.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: isatuximab, lenalidomide, and dexamethasone
What this could lead to: If successful, this combination could help eliminate remaining cancer cells after transplant, potentially leading to longer remission for multiple myeloma patients.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply to all patients. The drugs can cause side effects like infections, fatigue, and blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplasm, Residual plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Froedtert Hospital & the Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.